Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Initiation of FF/UMEC/VI after ICS/LABA treatment among Medicare Advantage-insured patients with asthma was associated with reduced rates of asthma-related exacerbations, ED and OP visits, and healthcare costs, highlighting the benefits of therapy escalation among this patient population.
Authors
- Alan P. Baptist (ORCID: https://orcid.org/0000-0001-8284-0027)
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Rosirene Paczkowski (ORCID: https://orcid.org/0009-0001-7151-4311)
- Alison Moore
- Robert C. Schell (ORCID: https://orcid.org/0000-0002-1252-0826)
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- Sergio Forero-Schwanhaeuser
- Guillaume Germain
- J. Klimek
Institutions
- Henry Ford Health System (US)
- Menlo School (US)
- GlaxoSmithKline (United States) (US)
- Group for Research in Decision Analysis (CA)
- Durham VA Medical Center (US)
- Impact (CA)
- Analysis Group (United States) (US)
- McMaster University (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1007/s12325-024-03083-6
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.33